58results about How to "Does not elicit an immune response" patented technology

The invention relates to a sgRNA targeting sequence of specific target pig MC4R gene and applications of the sgRNA targeting sequence, relating to a gRNA targeting sequence and applications. The sgRNA targeting sequence is CGTCTCGCGCTTGGACTCAG. The sgRNA targeting sequence can knock out or edit MC4R gene through a CRISPR/Cas9 system, and further eliminate the expression of MC4R, thus providing basis for preparing MC4R transgenic pigs. The sgRNA targeting sequence is applied to the field of genetic engineering.

The invention belongs to the technical field of biological pharmacy, and relates to a tumor targeting polypeptide-medicine coupling derivative, and a preparation method and application thereof. The tumor targeting polypeptide-medicine coupling derivative comprises targeting polypeptides, long effect polypeptides and medicine molecules, wherein the targeting polypeptides are connected onto the endC of the long effect polypeptides through flexible connecting peptides; fusion peptides are used as carriers of the medicine molecules; the medicine carriers and the long effect polypeptides in the fusion peptides are connected through chemical bonds; and the long effect polypeptides are polypeptide or protein structural domains having the affine mutual effects with human serum albumin. The tumortargeting polypeptide-medicine coupling derivative can be combined with the human serum albumin; the remaining half-life period in the blood circulation system can be obviously prolonged; the long-term effectiveness in the body is realized; the targeting and seepage into the tumor tissues or cells can be realized; then, free effect molecules are released in tumor tissue micro acid environments orin cells in through an acid hydrolysis mechanism; and a better anti-tumor efficiency is achieved.

The present invention discloses a kind of small peptide with the amino acid sequence of P-M-K-M-R-T-M or Y-E-P-K-I-R-G, and its preparation. The preparation process includes screening bacteriophage peptide library with B lymphocyte stimulus factor as target molecule to obtain B lymphocyte stimulus factor specifically combined small peptide and determining its sequence, and subsequent artificial synthesis of corresponding small peptide. The small peptide may be used in preparing medicine for treating B lymphocyte stimulus factor related diseases.

The invention discloses a method to prepare soluble human selenium-containing catalytic single-chain antibodies, belonging to biotechnology field. The method includes the following steps: with glutathione derivatives as target antigen, filtrating the recombinant phage display human single-chain antibody library through immune affinity selection method to obtain single-chain antibodies B3 and D8; assembling the single-chain antibodies to secretory procaryon or eucaryon expression vector; translating colon bacillus or yeast cell; expressing and purifying the single-chain antibody proteins in procaryon or eucaryon; introducing GPX catalytic group SeCys at the substrate combining sites of the antibodies through chemical mutation method or directly expressing the soluble single-chain antibody proteins which contain GPX catalytic groups at the substrate combining sites with auxotrophic colon bacillus through genetic mutation techniques to endue the antibodies with GPX catalytic activity. The method of the invention is simple and the human selenium-containing catalytic single-chain antibodies prepared with the method are of high catalytic activity; the proteins expressed by the antibodies are soluble; therefore the method is good for large-scale production and is of broad application prospect in biological pharmacy.

The invention relates to a mesenchymal stem cell cryopreserving liquid directly applied to veins and a preparation method. The cryopreserving liquid does not contain fetal calf serum, thereby not only having low price, but also being directly applied to intravenous injection, and having safety in clinical practice. The cryopreserving liquid of the invention can maintain more than 90% of mesenchymal stem cells to survive for more than two months and meet the demand that most of mesenchymal stem cells are required to be cured in a course of the treatment.

The invention belongs to the field of medicinal preparations, and relates to preparation and application of a cytomembrane biomimic lipoprotein targeted nanometer drug delivery system. An anti-obesitydrug is embedded with a reconstituted high-density lipoprotein (rHDL) in a lipoprotein family to form a drug loading core, P3 peptide is modified with a cytomembrane to form a bionic shell, a bionictargeted nanoparticle used for obesity treatment is constructed, and the nanoparticle has the following characteristics: (1) the P3 peptide modified cytomembrane bionic shell has good biocompatibilityand adipose tissue targeting, so that the conditioning and phagocytosis effects of an immunity system for the nanoparticle can be reduced, the body circulation time of the drug is prolonged, and theaccumulation of the drug in adipose tissues is increased; (2) an rHDL core drug carrier has high safety and good carrying property, a lipid soluble drug can be loaded in a core embedding manner, and the lipid soluble drug can be biologically degraded completely without causing an immune reaction; and (3) the adopted anti-obesity drug can stimulate adipose tissue angiogenesis and increase white adipose tissue browning, so that the obesity is cured through synergy of the mechanism.

The invention relates to the fields of medicines and medical instruments, and particularly relates to a preparation method for a gel scaffold for repairing articular cartilage injuries. The preparation method specifically comprises the following steps: (1) modifying sodium hyaluronate; (2) dissolving PLGA nano-particles of a controlled-release small molecular compound in the sodium hyaluronate modified in the step (1), and then adding with a photoinitiator to obtain a controlled-release small molecular compound-sodium hyaluronate gel compound system; and (3) injecting/filling the controlled-release small molecular compound-sodium hyaluronate gel compound system to the articular cartilage injuries to be repaired for being irradiated by an ultraviolet point light source, so as to obtain the gel scaffold for repairing articular cartilage injuries. The gel scaffold provided by the invention is high in plasticity, and capable of being randomly shaped according to the shapes of cartilage defects; harmful substances are not introduced in the whole process, and the gel scaffold can be used in vivo.

The invention relates to the field of pharmacy, and particularly relates to a multi-mode ultrasonic contrast agent and a preparing method thereof. Micro bubbles of the contrast agent are small and can enter tissue gaps, and developing time is stable. According to a technical scheme, mesoporous silicon covering gold nanorods adsorbs a paramagnet and liquid fluorocarbon, and the surface of the obtained product is modified with biocompatible hyaluronic acid to obtain the contrast agent having a targeting property. The contrast agent has stable physical and chemical properties and good biocompatibility, can be effectively used as a contrast agent for tumor diagnosis, and can enhance ultrasonic development, opto-acoustic development and magnetic resonance development. The application range of the contrast agent is wide.

The invention discloses a spinning solution and a method for preparing human serum albumin nanofibers or films by using the spinning solution. The method comprises the following steps of: mixing human serum albumin, trifluoroethanol, ammonium hydroxide or hydrochloric acid, and beta-mercatoethanol in a ratio to obtain the spinning solution; forming by using an electric spinner or a film pressing machine; and curing and drying to obtain the nanofibers, films and other solid objects respectively. After the human serum albumin materials are soaked in hot water and ethanol, and dried, the human serum albumin materials have high-strength physical and mechanical properties and are suitable for replacing the conventional clinical products, such as medical degradable suture lines, orthopaedic materials, intracavity and in-vitro hemostatic gauze, antiadhesive membranes and other medical auxiliary materials.

The invention provides a hUCMSCs (human umbilical cord mesenchymal stem cells) carrying a PEDF (pigment epithelial-derived factor) and modified with a recombinant lentivirus as well as a preparation method of the hUCMSCs. The hUCMSCs which carries a PEDF and is modified with the recombinant lentivirus secretes PEDF protein. According to the technical scheme, hUCMSCs have high expression of the PEDF protein with an efficient transgenic technology, the technical problem of continuous expression of the PEDF protein in eyes is solved, the immunogenicity of the hUCMSCs is low, and no immunoreaction can be caused when the hUCMSCs are injected into bodies to be used as a carrier of the PEDF protein.

The invention belongs to the technical field of a medicine preparation, and discloses an intragastric floating sustained release tablet of a praziquantel composition and a preparation method thereof. The intragastric floating sustained release tablet of the praziquantel composition comprises the following raw materials: 65-85 parts of praziquantel, 50-60 parts of hydroxypropyl-beta-cyclodextrin, 40-60 parts of hydroxypropyl methyl cellulose, and 30-50 parts of xanthan gum. The intragastric floating sustained release tablet of the praziquantel composition provided by the invention is good in sustained release effect, and the blood concentration curve of praziquantel after medicine administration is smoother, the bioavailability of the praziquantel is significantly improved, and popularization and application of the praziquantel are facilitated.

The invention discloses a composite Moringa oleifera sugar polypeptide-amino acid buccal tablet and a preparation method thereof. The buccal tablet comprises the following components in percentage by mass: 80-90% of Moringa oleifera protein peptide powder, 9-19% of sweetening agent and 0.5-1.5% of magnesium stearate, totaling 100%. The Moringa oleifera protein sugar polypeptide-amino acid product prepared by physical and enzymological techniques and a staged process. The molecular weight of the sugar polypeptides is 1-10KD, and the content is 17.5-21.7%; the amino acids have abundant varieties, and the content is enhanced to 6.33%; and the composite Moringa oleifera sugar polypeptide-amino acid buccal tablet has the effects of resisting oxidation, promoting mineral absorption and regulating the metabolic balance of the human body.

The invention discloses a tissue engineering cartilage framework as well as a preparation method and a application thereof. The preparation method of the tissue engineering cartilage framework comprises the following steps of (1) performing laser hole forming on natural cartilage tissues to obtain laser microporous cartilage tissues; (2) performing decellularization on the laser microporous cartilage tissues to obtain the tissue engineering cartilage framework.

The invention relates to a method for preparing the carrier RNA polyamide dendric polymer nanometer particles. The invention is characterized in that it uses polyamide dendric polymer as carrier whose amido group number is at 1:10 ratio with the phosphate group number of RNA, to form the polyamide dendric polymer RNA crosslink composite, while the average diameter is 85.64nm at 25Deg. C, with high package on RNA, high carriage, and improved anti-acid and anti-enzyme abilities of RNA, improved cell transfer rate, and the high-efficiency character of small molecule disturbance technique. The invention can be used in the treatment of liver cancer.

The invention belongs to the fields of anti-tumor targeted drug research and development, and especially relates to a composition, a preparation method and an application thereof in a killing cell strain. The present invention provides a composition comprising black phosphorus, 5-aminolevulinic acid, polyethylene glycol, and a transferrin receptor binding peptide. The present invention also provides a preparation method of the above composition, and the present invention provides the application of the above composition or a product obtained by the above preparation method for killing SAS, HSC-2 and HSC-3 cell strains. According to the experimental determination, compared with a positive control drug, the product prepared by the technical solution provided by the invention has a significant inhibitory effect on the growth and reproduction of the tumor cell strain, and can further promote the apoptosis of the tumor cell. The invention provides the composition, the preparation method andthe application thereof in the killing cell strain, which solve the problem that the tumor targeting drug has difficulty in balancing the in vivo stability, the targeted aggregation ability and the carrier degradation performance, and other technical defects in the prior art.

The invention provides an etomidate nano preparation. The etomidate nano preparation is prepared from the following raw materials in parts by weight: 10 parts of etomidate, 0-30 parts of pluronic and70-100 parts of lecithin. The etomidate nano preparation disclosed by the invention has the advantages of high safety, low toxicity, no irritating allergy, good biocompatibility, good bioavailabilityand high stability, and has practical application and popularization values.

The invention discloses a fusion protein capable of inhibiting tumor neovascularization and a production technology thereof. The fusion protein contains all sequences of mature human kallistatin and a carboxyl terminal peptide (CTP) of a human chorionic gonadotropin beta (hCGbeta) chain. The LA-Kal protein is expressed by adopting high-level secretion of CHO cells. Because the secreted protein level is high, the downstream purification is very convenient; and the purity of the protein can reach over 98 percent by two-step chromatography, so the protein is very convenient for process production.